YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ...(tiated from other approaches using opioi...)

Date:11/2/2009

tiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF met all endpoints in a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE YM BioSciences Inc.

'/>"/>

SOURCE YM BioSciences Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
2. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
3. OriGene Technologies Acquires Marligen Biosciences
4. Cytopia Merger with Toronto-based YM BioSciences Inc.
5. YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
6. Regado Biosciences To Present at the 2009 Japan Biopharma Partnering Conference on October 6, 2009
7. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
8. Neurocrine Biosciences Amends Corporate Headquarters Lease
9. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
10. YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO
11. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference